세계의 위암 시장 : KOL 인사이트

This comprehensive report delves into the current and future landscape of gastric cancer (GC) treatments, offering insights from 12 key opinion leaders (KOLs) across the US and Europe. It examines the evolving roles of HER2-targeted therapies such as trastuzumab and Enhertu, assesses the clinical and commercial implications of immuno-oncology agents including Keytruda, Opdivo, and Tevimbra, and evaluates the promise of emerging therapies like zolbetuximab, bemarituzumab, and zanidatamab. The report explores key challenges in GC management, the growing role of biomarkers in guiding treatment, and expectations for new combination strategies. Gain a detailed understanding of both approved and pipeline therapies, supported by expert insights on trial outcomes and future treatment dynamics.

Key Questions Answered:

• 1. What are the biggest unmet needs in gastric cancer treatment today?
• 2. How are gastric cancer patients typically treated in first- and second-line settings?
• 3. How is HER2 status influencing therapy selection in gastric cancer?
• 4. What impact have new approvals like Opdivo, Keytruda, Tevimbra, and Vyloy had on treatment strategies?
• 5. Which immuno-oncology approaches show the most promise in gastric cancer?
• 6. How are biomarkers being used to guide treatment decisions in GC?
• 7. What are expert views on emerging targeted therapies like bemarituzumab and zolbetuximab?
• 8. How is the gastric cancer treatment landscape expected to evolve over the next 3-5 years?

Key Brands:

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.